These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23728826)

  • 1. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.
    Waimann CA; Marengo MF; de Achaval S; Cox VL; Garcia-Gonzalez A; Reveille JD; Richardson MN; Suarez-Almazor ME
    Arthritis Rheum; 2013 Jun; 65(6):1421-9. PubMed ID: 23728826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
    Benbouazza K; Benchekroun B; Rkain H; Amine B; Bzami F; Benbrahim L; Atouf O; Essakalli M; Abouqal R; Dougados M; Hajjaj-Hassouni N
    BMC Musculoskelet Disord; 2011 Nov; 12():266. PubMed ID: 22111841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
    Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
    J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort.
    Benbouazza K; Rkain H; Benchekroun B; Amine B; Bzami F; Benbrahim L; Atouf O; Essakalli M; Abouqal R; Dougados M; Hajjaj-Hassouni N
    Joint Bone Spine; 2012 Jan; 79(1):43-6. PubMed ID: 21497534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et Al.
    Costedoat-Chalumeau N; Le Guern V; Piette JC
    Arthritis Rheumatol; 2014 Mar; 66(3):770. PubMed ID: 24574241
    [No Abstract]   [Full Text] [Related]  

  • 10. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
    Amoruso A; Sola D; Rossi L; Obeng JA; Fresu LG; Sainaghi PP; Pirisi M; Brunelleschi S
    Pharmacol Res; 2016 May; 107():308-314. PubMed ID: 27045818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.
    Cannon GW; Mikuls TR; Hayden CL; Ying J; Curtis JR; Reimold AM; Caplan L; Kerr GS; Richards JS; Johnson DS; Sauer BC
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1680-90. PubMed ID: 21905260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease.
    Garcia Popa-Lisseanu MG; Greisinger A; Richardson M; O'Malley KJ; Janssen NM; Marcus DM; Tagore J; Suarez-Almazor ME
    J Rheumatol; 2005 May; 32(5):913-9. PubMed ID: 15868630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
    Homer D; Nightingale P; Jobanputra P
    Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.
    Hodkinson B; Musenge E; Ally M; Meyer PW; Anderson R; Tikly M
    Clin Rheumatol; 2012 Apr; 31(4):613-9. PubMed ID: 22134750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease.
    Pasma A; Schenk CV; Timman R; Busschbach JJ; van den Bemt BJ; Molenaar E; van der Laan WH; Schrauwen S; Van't Spijker A; Hazes JM
    Arthritis Res Ther; 2015 Oct; 17():281. PubMed ID: 26449852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
    Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR
    Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.